India Cancer Diagnostics Market Developments, 2031

Key Insights

• According to the research report, "India Cancer Diagnostics Market Outlook, 2031," published by Bonafide Research, the India Cancer Diagnostics Market is expected to reach a market size of more than 3.99 Billion by 2031.
• India’s cancer diagnostics landscape is witnessing a major shift toward frugal innovation and indigenous assay manufacturing to overcome high import dependencies and expand testing access. Domestic biotechnology firms and diagnostic hubs are developing localized Real-Time PCR kits, liquid biopsy panels, and microfluidic point-of-care screening devices optimized for resource-constrained settings. A key technological breakthrough is the development of low-cost circulating tumor DNA (ctDNA) liquid biopsy assays and HPV-DNA self-sampling diagnostic kits tailored specifically to Indian genetic variations and socio-economic conditions. These affordable molecular diagnostic alternatives enable regional pathology laboratories and cancer centers to offer targeted companion diagnostic panels at a fraction of Western pricing, significantly broadening precision oncology adoption across Tier-2 and Tier-3 cities.
• To address severe practitioner shortages and bridge the diagnostic divide between urban tertiary hospitals and rural communities, Indian healthcare providers are aggressively deploying artificial intelligence (AI) across diagnostic imaging and pathology. AI algorithms are increasingly embedded into mobile thermal imaging platforms for non-contact breast cancer screening, low-dose CT scans for lung cancer, and automated liquid-based cytology for cervical screening. Concurrently, centralized corporate diagnostic chains are establishing cloud-based tele-pathology and digital histopathology networks. Whole-slide images generated at semi-urban satellite clinics can be transmitted instantaneously to specialized sub-specialists in major metros, standardizing turnaround times and diagnostic accuracy nationwide. Over 1,400,000 new cancer cases are diagnosed annually across India, placing an enormous operational load on public and private healthcare infrastructure.

Market Outlook

• The long-term trajectory for India's cancer diagnostics market is heavily anchored in government-backed public health initiatives aimed at early detection, primarily under the National Health Authority's Ayushman Bharat (PM-JAY) and the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD). State and central health authorities are systematically equipping Health and Wellness Centres (HWCs) and district hospitals with standardized screening infrastructure for oral, breast, and cervical cancers. Important national professional organizations, research councils, and advocacy bodies establishing clinical guidelines and driving diagnostic standards include the Indian Council of Medical Research (ICMR), the Indian Society of Medical and Pediatric Oncology (ISMPO), the Association of Radiation Oncologists of India (AROI), the Molecular Pathology Association of India (MPAI), and the Central Drugs Standard Control Organization (CDSCO). Key commercial diagnostic leaders and healthcare networks driving testing distribution include Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Metropolis Healthcare, Dr. Lal PathLabs, SRL Diagnostics (Agilus Diagnostics), Strand Life Sciences, Mapmygenome, MedGenome, and Molbio Diagnostics.
• A critical catalyst shaping India's market outlook is the ongoing regulatory modernization enforced by the Central Drugs Standard Control Organisation (CDSCO) under the Medical Devices Rules (MDR). Standardized regulatory approval pathways for in vitro diagnostics (IVDs), companion diagnostics, and Next-Generation Sequencing (NGS) panels are raising quality standards while curbing sub-standard testing reagents. As public and private insurance payers progressively incorporate molecular biomarker profiling, multi-gene NGS testing, and liquid biopsies into covered oncology packages, diagnostic providers will expand integrated diagnostic pathways that seamlessly combine digital pathology, AI-powered imaging, and precision genomics across all Indian states and union territories.

Market Dynamics

Driver: High disease incidence and government-backed Ayushman Bharat expansion
The primary driver expanding India's cancer diagnostics market is the heavy domestic burden of malignant neoplasms combined with centralized public health mandates under Ayushman Bharat (PM-JAY) and the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD). With over 1.4 million new cancer cases registered annually across India dominated by high incidences of oral, cervical, breast, lung, and gastrointestinal cancers the Indian government is prioritizing early screening to prevent late-stage presentations. Under Ayushman Bharat and the expanding network of Health and Wellness Centres (HWCs), public health authorities are institutionalizing community-level screening protocols for age-eligible populations.
Challenge: Severe urban-rural infrastructure disparities and out-of-pocket expense pressures
The most critical bottleneck confronting the Indian cancer diagnostics sector is the severe geographic disparity in diagnostic infrastructure, compounded by heavy out-of-pocket healthcare expenditure. Advanced diagnostic facilities such as high-throughput Next-Generation Sequencing (NGS) laboratories, specialized immunohistochemistry (IHC) centers, and high-field PET-CT imaging hubs are overwhelmingly concentrated in major tier-1 metropolitan cities like Delhi NCR, Mumbai, Bengaluru, Chennai, and Hyderabad.
Trend: Rapid integration of AI-powered screening, digital tele-pathology, and home sample collection
A defining structural trend reshaping the Indian diagnostic landscape is the rapid adoption of artificial intelligence (AI), digital pathology networks, and home-based screening models to bridge the rural-urban care gap. To compensate for the deficit of specialized radiologists and anatomical pathologists, major diagnostic providers and public health partners are deploying AI-driven algorithms for pre-screening chest X-rays/CT scans for lung nodules and evaluating mammograms/thermal imaging for breast cancer.

Segment Analysis

India Cancer Diagnostics By Product Type
• India’s cancer diagnostics consumables and reagents segment is shaped by the coexistence of domestic diagnostic manufacturers, imported specialty products, large private laboratory networks, and public-sector healthcare facilities. Key products include immunohistochemistry antibodies, tissue-staining reagents, PCR kits, nucleic acid extraction materials, sequencing reagents, and molecular biomarker assays. A distinctive market feature is the need to balance advanced testing capabilities with affordability and dependable supply, particularly for laboratories serving patients from different socioeconomic backgrounds. Indigenous assay development and locally manufactured diagnostic kits offer opportunities to reduce dependence on imported products, while specialized molecular tests continue to require stringent validation and quality control.
• India’s cancer diagnostics instruments segment includes molecular analyzers, PCR systems, sequencing platforms, automated tissue processors, immunostaining equipment, microscopes, digital pathology scanners, and diagnostic imaging systems. The market is distinguished by differences in infrastructure between metropolitan cancer centers, private hospital groups, regional laboratories, and public healthcare facilities. Large tertiary institutions may require advanced genomic profiling and automated pathology workflows, while facilities with limited specialist staffing often prioritize robust equipment that is easier to operate and maintain.



India Cancer Diagnostics By Technology
• India’s in vitro diagnostic testing segment encompasses molecular assays, immunoassays, PCR-based testing, next-generation sequencing, and other laboratory techniques used to identify cancer-associated biomarkers. A distinctive characteristic is the growing role of domestic biotechnology companies and specialized reference laboratories in extending access to advanced testing beyond major oncology hospitals. Molecular diagnostics can help classify tumors, identify treatment-relevant genetic alterations, and assess inherited cancer susceptibility in selected patients.
• Diagnostic imaging in India includes mammography, ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography used for cancer detection, staging, biopsy guidance, and follow-up. A distinctive market characteristic is the need to connect advanced imaging capabilities in major hospitals with diagnostic access in smaller cities and underserved regions. Imaging is especially important when suspicious lesions must be localized before tissue sampling or when treatment response needs to be assessed.
• Biopsy technologies in India include fine-needle aspiration, core-needle biopsy, endoscopic sampling, image-guided biopsy, and surgical tissue collection. The segment is distinguished by the importance of obtaining an accurate diagnosis while managing procedural costs, patient access, and the availability of specialist services. Biopsy specimens must be handled carefully because they may be required for histopathology, immunohistochemistry, and molecular profiling. In facilities without advanced laboratory capabilities, specimens may need to be transported to referral centers, making preservation, labeling, and logistics important considerations.

India Cancer Diagnostics By Application
• India’s breast cancer diagnostics segment is influenced by public screening initiatives, clinical breast examinations, diagnostic imaging, biopsy services, and biomarker testing. A distinctive feature is the need to connect early identification of suspicious abnormalities with timely confirmatory diagnosis, particularly where access to specialist imaging and pathology varies by location. Mammography and ultrasound support lesion assessment, while fine-needle aspiration, core-needle biopsy, and histopathology help establish the diagnosis. Immunohistochemistry for hormone receptors and HER2 is important for treatment planning, with additional molecular testing used in selected cases.
• India’s colorectal cancer diagnostics segment combines clinical evaluation, endoscopic examination, biopsy, histopathology, and molecular testing. A distinctive characteristic is the need to improve access to confirmatory diagnostic services while ensuring that patients with suspicious symptoms or findings can progress efficiently from initial assessment to specialist investigation. Colonoscopy enables direct visualization and tissue sampling, while pathology establishes tumor classification. Molecular testing can provide treatment-relevant information, including mismatch repair status and selected genetic alterations, depending on the clinical context.
• India’s lung cancer diagnostics segment is shaped by the need to combine radiological evaluation, tissue sampling, histopathology, and molecular testing. Computed tomography helps identify suspicious lesions, while bronchoscopy and image-guided biopsy provide specimens for confirming malignancy and determining tumor subtype. A distinctive feature is the challenge of obtaining adequate tissue while limiting procedural risk, especially when lesions are difficult to access or patients have limited tolerance for invasive procedures. Molecular testing for actionable alterations, including EGFR and other clinically relevant biomarkers, supports treatment selection in appropriate cases.
• India’s prostate cancer diagnostics segment includes prostate-specific antigen testing, clinical evaluation, imaging, prostate biopsy, and histopathological assessment. Its distinctive market characteristic is the need to identify clinically significant disease while avoiding unnecessary invasive procedures and overdiagnosis. Access to specialist urology services, multiparametric MRI, and pathology expertise can influence the diagnostic pathway available to patients. Biopsy and histopathological grading remain important for confirming malignancy and assessing disease characteristics, while molecular and genetic testing can support selected cases involving inherited susceptibility or advanced disease management.
• The other applications segment includes cervical, oral, ovarian, stomach, liver, pancreatic, kidney, skin, hematological, and other malignancies. Its defining characteristic is the diversity of screening and diagnostic methods required across India's cancer care landscape. Public health programs place particular emphasis on early identification of selected common cancers, including oral, breast, and cervical cancers, while specialized hospitals provide more complex investigations for other malignancies. Cervical cancer diagnostics can involve human papillomavirus testing, cytology, and histopathology; oral cancer assessment may begin with visual examination followed by biopsy; and hematological malignancies often require flow cytometry and specialized molecular testing.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Consumables and reagents
• Instruments

By Technology
• IVD testing
• Anatomic pathology
• Diagnostic imaging
• Biopsy

By Application
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Others